Only 7% of consumers rate social health information as highly accurate, raising the stakes for healthcare and pharma marketing content credibility.
Backlash over Medvi’s telehealth business after a NYT report signals increasing scrutiny of online health ads.
Pharmacies and telehealth brands are racing to capture GLP-1 pill users, making strong customer service and patient support essential.
Rapid share gains in India come at the expense of branded drugs, challenging premium pricing models and raising the bar for new entrants.
Consumer usage is widespread, but their shaky brand trust and safety skepticism makes physician backing critical.
Rising AI adoption among younger consumers for mental health and emotional support makes safe chatbot design table stakes, especially as lawsuits mount.
Mega rounds now dominate late-stage digital health dealmaking, with startups attracting capital through scale, proven market fit, and AI value.
The FDA's 2027 budget would define specific misbranding violations in law, potentially speeding enforcement and raising compliance risks.
73% of US adults miss routine tests as cost fears and confusion over bills stall action.
Consumers may be drawn to unregulated peptide products for now, but long-term brand success in this space will depend on transparency and clear education.
Wellness culture drives increased consumer health spending, but brands still must avoid shame-based messaging that undermines trust.
New drug tariffs of up to 100% spare Big Pharma dealmakers, but force midsize and smaller companies to weigh the steep levies versus compliance costs.
Around half of Americans are turning to the AI tool for clarity on test results and a second opinion, but still default to doctors for prescription questions and image analysis.
Healthcare affordability now ranks above inflation and crime as Americans’ top concern, creating an opportunity for healthcare brands to showcase patient-first efforts to reduce costs amid rising scrutiny.
Patients mostly want AI use to supplement professional advice, but stigma prevents them from admitting it. Providers and marketers can guide smarter, transparent AI use.
The stage is set for a market share battle over efficacy, convenience, and brand recognition.
The FDA’s biologics arm cited several oncology brands for misleading claims, intensifying the agency’s broader pharma marketing enforcement.
Novo is testing tiered subscriptions to boost Wegovy adherence—but whether patients stay on their meds will hinge on post-prescription support from its telehealth partners.
CVS is testing pharmacy-only stores to see if drugstores can drop snacks and still succeed as care hubs.
Its exclusive Insilico licensing reflects pharma’s move to AI-driven early discovery to speed development and trim costs.